Holostem Terapie Avanzate S.r.l. news
Epidermolysis bullosa (EB), better known as butterfly baby disease, is a genetic disorder that involves the continuous formation of bullous lesions on the skin, due to very small mechanical trauma and minimal rubbing, which strongly impact the quality of life of these patients. Depending on the type of mutated gene, it is distinguished in different forms, of which the most severe are Junctional and Dystrophic. In 2017, the story of Hassan, a Syrian “butterfly child&rdq
Modena, September 27th, 2021 – On October 1st, Holostem Terapie Avanzate and the Centre for Regenerative Medicine “Stefano Ferrari” at the University of Modena and Reggio Emilia – in collaboration with the “Le Ali di Camilla” Association – will organise a virtual tour of their laboratories in Modena. HoloTour will take the public inside state-of-the-art facilities, home to research and development of new advanc
On Thursday 3 June, the second event dedicated to the exploration of the assets identified during 2020 in the in-depth analysis of the potential and prospective attractiveness carried out on the health and wellness sector in Emilia-Romagna will be held. The theme of this meeting, which will start at 5 p.m., is advanced therapies: technically called ATMPs (Advanced Therapy Medicinal Products), they are therapies based on cells, tissues
Modena, 23 April 2021 – The European Research Council (ERC) yesterday announced the winners of the 2020 Advanced Grants. The grants, worth a total of €507 million, will support 209 researchers across Europe. Eight projects were won by researchers working in Italy, including the project presented by Michele De Luca, Director of the “Stefano Ferrari” Centre for Regenerative Medicine at the University of Modena and Reggio Emilia (Unimore) and co-founder and Scientific Dire
Parma and Modena, 16 June 2020 – Chiesi Farmaceutici, international research-focussed group (Chiesi Group), and Holostem Terapie Avanzate, top Italian biotech company entirely dedicated to the development, production, registration and distribution of medicinal products for advanced therapies, announce the signing of a contract for the transfer of the business branch of Holoclar®, an autologous stem-cell therapy for the treatment of patients with severe